NCT07865871Not yet recruitingEarly phase 1
Role of Inhaled Polymyxin as an Adjunct to Intravenous Therapy in Multidrug Resistant Ventilator-associated Pneumonia in Stroke Patients
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This study investigates whether adjunctive inhaled colistin enhances clinical recovery and microbiological clearance in multidrug resistant ventilator-associated pneumonia in stroke patients
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- First submitted
- 5 Oct 2026
- Start date
- 10 Oct 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Stroke
- NCT number
- NCT07865871
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 78
- From 10 Oct 2026 to the primary completion date, 1 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with cultures sensitive to colistin will be excluded.
Who the study is looking for
- \-
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.